ClinicalTrials.gg
Not yet recruitingNCT07487194Updated Sep 28, 2026

Global Utilization And Registry Database for Improved preservAtion of doNor Pancreata (GUARDIAN-PANCREAS)

An observational study in Pancreas (Including SPK) Transplantation, Pancreas Diseases and Pancreas Transplant Rejection, sponsored by Paragonix Technologies. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Paragonix Technologies · Observational

How we know

Updated Sep 28, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Sex
All
01

Study summary

The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving pancreas transplants using donor pancreata transported via the PancreasPak system. These results will be compared to standard of care outcomes, as well as other preservation methods.

Read the detailed description

GUARDIAN-PANCREAS is a post-market, observational registry of adult transplant recipient patients whose donor pancreas was preserved and transported within the PancreasPak. The data is being collected retrospectively from medical records of patients already transplanted before the initiation of the registry and any new patients who meet the eligibility criteria.

About 1000 subjects meeting the study inclusion and exclusion criteria will be enrolled into the study at about 15 clinical sites.

Candidates that fit the eligibility criteria and have had their donor pancreas transported with a Paragonix product or a standard of care method can be enrolled. The baseline characteristics and outcomes of the two groups will be compared.

02

Conditions studied

  • Pancreas (Including SPK) Transplantation
  • Pancreas Diseases
  • Pancreas Transplant Rejection
  • Pancreas Transplant; Complications

Browse trials for

03

In context

Pancreatic Diseases

184 studies on the registry are indexed under Pancreatic Diseases; 61 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 363 across 76 observational studies indexed under Pancreatic Diseases.

Browse Pancreatic Diseases studies →

Lead sponsor

Paragonix Technologies is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who have received a pancreas transplant at centers that use the PancreasPak device.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult or pediatric recipients of pancreas alone, simultaneous pancreas-kidney, or pancreas after kidney transplant

Exclusion criteria

Exclusion Criteria:

  • Donor pancreata that do not meet institutional clinical requirements for transplantation
  • Simultaneous pancreas-kidney transplant recipients who received donor organs from multiple donors
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • PancreasPak patient

    Patients whose donor pancreas was transported with the PancreasPak device.

    Device: PancreasPak

  • Standard method patients

    Patients whose donor pancreas was transported with a method other than the PancreasPak device.

Interventions

  • DevicePancreasPak

    The PancreasPak Donor Preservation System is a FDA cleared and CE-marked medical device intended to be used for the static hypothermic preservation of donor pancreata during transportation and eventual transplantation using cold preservation solutions indicated for use in donor pancreata transplantation. The intended organ preservation time for the PancreasPak system is up to 21 hours.

06

What researchers measure

Primary outcomes

  1. Graft dysfunction

    The percentage of subjects in each cohort who experience graft dysfunction post-transplant.

    Time frame: Post-transplant through 1 year post-transplant

  2. Pancreatitis

    The percentage of subjects in each cohort who experience pancreatitis post-transplant.

    Time frame: Post-transplant through 1 year post-transplant

  3. Primary Non-Function

    The percentage of subjects in each cohort who primary non-function post transplantation.

    Time frame: Post-transplant through 7 days post-transplant

  4. Length of Hospital Stay

    How many days the patients stays in the hospital post-transplant.

    Time frame: 1 year

  5. Surgical Complications

    The percentage of subjects in each cohort who experience surgical complications.

    Time frame: Post-transplant through 1 year post-transplant

  6. Insulin Dependence

    The percentage of subjects in each cohort who experience insulin dependence post-transplant.

    Time frame: Post-transplant through 1 year post-transplant

  7. Graft Failure

    The percentage of subjects in each cohort who develop graft failure post-transplant.

    Time frame: Post-transplant through 1 year post

  8. Survival

    The percentage of subjects in each cohort who survive through 1 year post-transplant.

    Time frame: Post-transplant through 1 year post

Secondary outcomes

  1. Length of ICU Stay

    How many days the patient stayed in the ICU post-transplant.

    Time frame: 1 year

  2. Interventions for Anastomotic Complications

    The percentage of subjects in each cohort who required interventions due to anastomotic complications.

    Time frame: Post-transplant through 1 year post-transplant

  3. Intervention for Vascular Complications

    The percentage of subjects in each cohort who required interventions due to vascular complications.

    Time frame: Post-transplant through 1 year-post transplant

  4. Medications

    The percentage of subjects in each cohort who required the use of various medications.

    Time frame: Post-transplant through 1 year post-transplant

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Jun 2031, 53 months later.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jan 2027, on Sep 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 23, 2026
StartEst.
Jan 2027was Jun 2026
Primary completionEst.
Jun 2031
CompletionEst.
Jan 2032
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Jan 2027
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Start date Jun 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07487194
Lead sponsor
Paragonix Technologies
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jun 2031 (estimated)
Completion
Jan 2032 (estimated)
Last update
Sep 28, 2026

Study contacts

Amanda Schreiner
Contact
aschreiner@paragonixtechnologies.com
781-428-4153 ext. 22
Julia Hersum
Contact
julia@paragonixtechnologies.com
781-428-4153 ext. 4

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion